^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TUBB3 overexpression

    i
    Other names: TUBB3, Tubulin beta 3 class III
    Entrez ID:
    10381
    Related biomarkers:
    Expression
    CNA
    1year
    Predictive and Prognostic Value of TUBB3, RRM1, APE1, and Survivin Expression in Chemotherapy-Receiving Patients with Advanced Non‑Small Cell Lung Cancer. (PubMed, Asian Pac J Cancer Prev)
    The expression levels of TUBB3 and RRM1 in NSCLC cells are potential predictive biomarkers, but not prognostic factors, of response to chemotherapy in patients with NSCLC receiving the Car/Pac regimen.
    Journal • Metastases
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • TUBB3 (Tubulin beta 3 class III) • RRM1 (Ribonucleotide Reductase Catalytic Subunit M1)
    |
    TUBB3 overexpression • BIRC5 expression • TUBB3 expression • BIRC5 overexpression • TUBB3 underexpression
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel
    over1year
    Clinicopathological significance of TUBB3 in upper tract urothelial carcinoma and possible application in urine cytology. (PubMed, Pathol Int)
    The findings suggest the importance of TUBB3 in tumor progression and its potential application as a biomarker for high-grade disease and the prognosis of UC. Moreover, combination with TUBB3 immunostaining might improve the diagnostic accuracy of urine cytology.
    Journal • Cytology
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • TUBB3 (Tubulin beta 3 class III)
    |
    HER-2 expression • EGFR expression • TP53 expression • TUBB3 overexpression • CD44 expression • TUBB3 expression
    over1year
    Targeting hormone-resistant breast cancer cells with docetaxel: a look inside the resistance. (PubMed, Cancer Drug Resist)
    Aim: The study aims to analyze the effect of long-term incubation of ERα-positive MCF7 breast cancer cells with 4-hydroxytamoxifen (HT) on their sensitivity to tubulin polymerization inhibitor docetaxel. The expression of cyclin D1 decreased (2.8-fold) only in resistant cells after 4 nM docetaxel treatment, while this marker was unchanged in parental MCF7 breast cancer cells. Further development of taxane-based chemotherapy for hormone-resistant cancer looks highly promising, especially for cancers with low TUBB3 expression.
    Journal • PARP Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • TUBB3 (Tubulin beta 3 class III)
    |
    ER positive • CCND1 expression • TUBB3 overexpression • TUBB3 expression
    |
    docetaxel • tamoxifen
    over2years
    Class III β-Tubulin Expression Is of Value in Selecting nab-Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. (PubMed, Pancreas)
    Class III β-tubulin might be a predictive factor for the response of GnP, but not a prognostic factor for OS, helping the selection of an optimized first-line chemotherapy regimen for unresectable PDAC.
    Retrospective data • Journal
    |
    TUBB3 (Tubulin beta 3 class III)
    |
    TUBB3 overexpression • TUBB3 expression
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium